By Mill Chart
Last update: Sep 26, 2023
For growth-minded investors, high revenue and EPS growth are key criteria. Today, we'll examine whether HALOZYME THERAPEUTICS INC (NASDAQ:HALO) fits the bill for growth investing, particularly as it forms a base and hints at a potential breakout. Remember, due diligence is essential, but HALOZYME THERAPEUTICS INC has caught our attention on our screen for growth with base formation. It may warrant additional investigation.
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:HALO scores a 8 out of 10:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:HALO has received a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:HALO, the assigned 8 is noteworthy for profitability:
ChartMill takes into account not only the Technical Rating but also assigns a Setup Rating to each stock. This rating, on a scale of 0 to 10, reflects the degree of consolidation observed based on short-term technical indicators. Currently, NASDAQ:HALO exhibits a 7 setup rating, indicating its consolidation status in recent days and weeks.
Although the technical rating is bad, HALO does present a nice setup opportunity. We see reduced volatility while prices have been consolidating in the most recent period. There is a support zone below the current price at 38.50, a Stop Loss order could be placed below this zone.
More Strong Growth stocks can be found in our Strong Growth screener.
Our latest full fundamental report of HALO contains the most current fundamental analsysis.
For an up to date full technical analysis you can check the technical report of HALO
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
HALOZYME THERAPEUTICS INC
NASDAQ:HALO (4/26/2024, 7:00:02 PM)
After market: 38.88 +0.31 (+0.8%)38.57
+0.11 (+0.29%)
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr....
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results...
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech is an industry full of opportunity. It’s also known as one of the...
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...